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ABSTRACT
Introduction: Sickle cell disease (SCD) is caused by a mutation in the HBB gene which is key for making
a component of hemoglobin. The mutation leads to the formation of an abnormal hemoglobin
molecule called sickle hemoglobin (HbS). SCD is a chronic, complex disease with a multiplicity of
pathophysiological targets; it has high morbidity and mortality.
Hydroxyurea has for many years been the only approved drug for SCD; hence, the development of
new therapeutics is critical.
Areas covered: This article offers an overview of the key studies of new therapeutic options for SCD.
We searched the PubMed database and Cochrane Database of Systemic Reviews for agents in early
phase clinic trials and preclinical development.
Expert opinion: Although knowledge of SCD has progressed, patient survival and quality of life
must be improved. Phase II and phase III clinical trials investigating pathophysiology-based novel
agents show promising results in the clinical management of SCD acute events. The design of long-
term clinical studies is necessary to fully understand the clinical impact of these new therapeutics
on the natural history of the disease. Furthermore, the building of global collaborations will
enhance the clinical management of SCD and the design of primary outcomes of future clinical
trials.
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Sickle cell disease (SCD) is an hemoglobinopathy which affects
approximately 100,000 individuals in the United States and
almost 20,000–25,000 subjects in Europe, mainly immigrants
from endemic areas such as sub-Saharan Africa to European
countries [1–4]. Estimates of the number of affected newborns
in 2010 are of approximately 312,302 subjects with 75.5%
being born in Africa [5]. The invalidating impact of SCD on
patient survival, quality of life and cost for health systems [2],
requires the development of new therapeutic options to treat
sickle cell-related acute and chronic complications. SCD is
caused by a point mutation in the β-globin gene resulting in
the synthesis of pathological hemoglobin S (HbS). HbS dis-
plays peculiar biochemical characteristics, polymerizing when
deoxygenated with an associated reduction in cell ion and
water content (cell dehydration), increased red cell density
and further acceleration of HbS polymerization [6–8].
Pathophysiological studies have shown that dense, dehy-
drated red cells play a central role in acute and chronic clinical
manifestations of SCD, in which intravascular sickling in capil-
laries and small vessels leads to vaso-occlusion and impaired
blood flow with ischemic/reperfusion injury [6,9–12]. In micro-
circulation, vaso-occlusive crisis (VOC) result from a complex
and still partially known scenario, involving the interactions
between different cell types, including dense red cells,
reticulocytes, abnormally activated endothelial cells, leuko-
cytes, platelets, and plasma factors (Figure 1) [6,10,11,13–15].
Acute VOCs have been associated with increased expression of
pro-adhesion molecules such as vascular adhesion molecule-1
(VCAM-1), intracellular adhesion molecule-1 (ICAM-1) or selec-
tins [6,10,13,14,16,17]. These molecules are important in
recruitment and adhesion of both neutrophils and sickle red
cells to the abnormally activated vascular endothelial surface
[13,18].
Recently, in SCD mice exposed to hypoxia/reoxygenation
(H/R) to mimic VOC, we highlighted the novel contribution of
altered pro-resolving events in organ damage due to
ischemic/reperfusion stress (Figure 1, inset) [19]. Indeed, in
humanized SCD mice, the failure of acute inflammatory reso-
lution sustains the amplified inflammatory response to H/R,
making SCD mice more vulnerable to inflammatory vasculo-
pathy (Figure 1) [19]. Thus, targeting pro-resolving mechan-
isms may represent an interesting new therapeutic strategy to
be tested in appropriate human trials in SCD.
This review provides an overview on the more relevant
studies on new therapeutic options for SCD. We did
a systematic review using specific search strategy, carried out
the review of PubMed database, Cochrane Database of
Systemic Reviews on early-phase clinic trials, and molecules
in pre-clinical development for SCD diagnosis.
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2. Novel therapeutic strategies to treat sickle cell
disease
In the last two decades, the availability of mouse models for
SCD has allowed both characterization of the pathogenesis of
sickle cell-related organ damage(s) and identification of patho-
physiology-based new therapeutic options in addition to
hydroxyurea (HU) [6,8,13,14,20–22]. This is in agreement with
the reported strong link between scientific publications on
rare disease and orphan drug designation [23]. In addition,
FDA and EU community has incentivized the development of
drugs with orphan designation status to increase therapeutic
options for rare diseases such as SCD.
As shown in Table 1, pathophysiology-related novel ther-
apeutic strategies for SCD can be divided into:
● Agents which reduce/prevent sickle red cell dehydration
or red cell sickling or HbF inducers to delay;
● Agents targeting SCD vasculopathy and sickle cell-
endothelial adhesive events;
● Anti-oxidant agents.
Among the agents preventing red cell sickling, the oral direct
anti-sickling agent GBT440 has been shown to be beneficial in
SCD (Figure 2). GBT440 (or voxelotor) blocks HbS intermolecular
contacts, preventing the generation of HbS fibers and red cell
sickling [24–28]. GBT440 has been shown (i) to ameliorate in vitro
SCD red cell features such as red cell deformability or viscosity
and (ii) to improve sickle red cell survival with decrease reticulo-
cyte count [24–28]. Preliminary data on phase I/II double-blind
placebo study with GBT440 (voxelotor) in healthy volunteers and
few SCD patients show safety and tolerability associated with an
amelioration of hemolytic indices and a reduction in reticulocyte
count (#NCT02285088) [29–32]. A phase III clinical trial is on-
going to evaluate whether the preliminary evidence of beneficial
clinical effects might be transferable in patients with severe,
symptomatic SCD (NCT03036813). In addition, FDA has recently
defined voxelotor as breakthrough therapy for SCD [33].
Noteworthy, new anti-sickling molecules related to voxelotor
such as GBT1118 are under functional characterization to expand
the choice on anti-sickling agents [34–37].
In addition to HU, fetal hemoglobin (HbF) inducers such as
decitabine or pomalidomide have been recently reported to
reduce HbS polymerization and increase red cell survival [38–46].
Decitabine (Dec) is an analogue of 5-azacitidine acting as HbF
inducers through the inhibition of DNA methyltransferase
(DNMT). The major limitation of this molecule is related to its
bioavailability and concentration. A recent report on phase I/II
clinical trial with Dec combined with tetrahydrouridine (THU), an
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Figure 1. Schematic model of sickle cell-related acute vaso-occlusive crisis (VOCs), which induces hypoxia/reoxygenation (H/R) damage. This induces an
inflammatory response, that requires a pro-resolving phase to control and reduce the H/R cellular and tissue injury. In sickle cell disease (SCD), the amplified
inflammatory response and the lack in pro-resolving events result in vascular vulnerability and dysfunction. In SCD, altered resolution leads to vasculopathy, tissue
damage, and disease progression. 17R-RvD1 has multi-pronged effects that revert the hyper-inflammatory phenotype, promote resolution, and prevent damage to
organs affected in SCD. In experimental SCD, 17R-RvD1 reduces neutrophil-endothelial cell interactions, blunts leukocyte infiltration in lungs and kidney following H/
R, thus limiting collateral injuries, and modifies molecular mechanisms underlying inflammation such as NF-κB, endothelin 1 values; vascular activation markers, and
microRNAs miR-126 and let7c. Inset. Schematic representation of the unbalance in the inflammatory response to H/R stress in SCD. Pro-inflammatory events are
preponderant on pro-resolving process, allowing tissue damage and disease progression. Modified from [19].
Matte A, Recchiuti A, Federti E, et al. Resolution of sickle cell disease-associated inflammation and tissue damage with 17R-resolvin D1. Blood. 2019;133 [3]:252–265.
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inhibitor of cytidine deaminase, has shown promising pharmaco-
kinetic data for future exploitation in trial with SCD patients
[40,41,45,46]. Pomalidomide is a potent HbF inducer through the
acetylation of key region in γ-globin gene. Some synergistic effects
of pomalidomide and HU have been described [38].
Recently, IMR-687, selective inhibitor of phosphodiesterase-
9 (PDE-9), has been tested in vitro and in vivo in humanized
model for SCD [47]. IMR-687 is an oral PDE-9 inhibitor. In SCD
mice, IMR-687 acts as a multimodal molecule: increasing HbF
synthesis with reduction of sickling modulating inflammatory
response, being protective against hypoxia-reoxygenation
damage that occurs in acute VOCs [47]. The authors propose
IMR-687 to be tested alone or in combination to lower dosage
of HU in SCD subjects non-responder to HU. On-going rando-
mized multicentric, placebo-controlled study-phase 2
(#NCT03401112) designed to evaluate the safety and tolerabil-
ity of IMR-687 in SCD patients.
2.1. Agents targeting SCD vasculopathy and sickle
cell-endothelial adhesive events
In SCD, anti-adherence therapeutic strategies might represent
an interesting, novel therapeutic strategy to prevent the gen-
eration of acute VOCs and to lessen SCD related organ
damage (Figure 2). The anti-adherence therapeutic options
might be divided into three groups based on their mechanism
of action:
a. Molecules interfering with the physical properties of the
red cell-endothelial adhesion process;
b. Molecules specifically interfering with sickle cell-
endothelial adhesive mechanisms;
c. Molecules modulating inflammatory pathways involved
in sickle cell endothelial adhesion;
d. Molecules affecting platelet function.
Among these molecules, growing attention has been devoted
to inhibitors of Selectin as either pan-selectin inhibitor
(Rivipansel) or P-selectin inhibitor (Crizanlizumab). Selectins
are a family of molecules mediating adhesion of blood cells
with activated vascular endothelial cells, and play a key role in
leukocyte recruitment as well as in sickle red cell adhesion to
inflammatory-activated vascular endothelium. In addition, stu-
dies have shown that P-selectin are increased in plasma of
SCD patients [48–53]. Different therapeutic strategies have
been developed, to block selectins: (i) pan-Selectin antagonist
(GMI-1070, rivipansel); (ii) humanized anti-P-Selectin antibody
(SelG1, crizanlizumab); (iii) P-selectin-aptamer; and (iv) sevu-
parin [13,14,17,22,50,52,54–59].
Rivipansel is a glycomimetic pan-selectin antagonist, which
was tested in phase I and phase II studies in SCD. Rivipansel
showed a safe profile, reducing the levels of E-Selectin in SCD
patients during acute VOCs [54,60]. In phase II study, rivipansel
beneficially affected the number of pain crisis in a small num-
ber of SCD subjects (#NCT01119833). However, these data
were obtained including some SC patients, which generates
some difficulties in their interpretation. When this review was
under editing, preliminary data of the phase 3 trial with
Rivipansel (RESET) were released. Rivipansel treatment did
not modify the time of patient discharge for acute VOCs





Table 1. Early and late phase clinical trial in sickle cell disease (SCD).
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Phase I/II Decitabine combined with tetrahydrouridine, an inhibitor of cytidine deaminase, has shown promising




GBT440 is an oral direct anti-sickling agent, to be beneficial in SCD. GBT440 (or voxelotor) blocks HbS
intermolecular contacts, preventing the generation of HbS fibers and red cell sickling (#NCT02285088).













Humanized anti-P-Selectin antibody (SelG1, crizanlizumab; SUSTAIN, #NCT0185361). [17, 58, 59]
Phase I/II clinical
trial
SCA411: DHA ester in combination with HU in children with SCD (n = 67 individuals) 20–36 mg/kg/day
for 8 weeks
L-arginine supplementation in combination with HU in SCD patients
L-Citrulline supplementation in SCD patient under steady state condition (n = 8 individuals)
IMR-687: phosphodiesterase-9 inhibitor safety and tolerability in SCD (enrolling)
Olinciguat: oral sGC stimulators safety and tolerability in SCD (enrolling)
[47, 82–90,
97, 100]
Pre-clinical studies ● Resolvin: 17R-RvD1-humanized mouse model for SCD
● IMR-687: phosphodiesterase-9 inhibitor-in vitro, ex vivo and in vivo studies in humanized SCD mice.
● Factor H and 19–20 FH fragment- ex vivo model
[19, 47, 62]
Oxidative stress Phase III clinical
trial
● L-Glutamine. Glutamine is involved in GSH metabolism. A multicenter, randomize, placebo-controlled
double-blind phase III clinical trial with L-glutamine (0.3 g/kg twice a day) supplementation reduced





● NAC, an exogenous thiol donor. A clinical trial with high dose of NAC during acute VOCs related to SCD
is ongoing (#NCT 01800526).
● GA exudates mechanically extracted from Acacia senegal (#NCT 02467257).
[103–105,
110]
HU: hydroxyurea, SCD: sickle cell disease; HbS: hemoglobin S; DHA: docosahexaenoic acid; RvD: resolving-D; VOCs: vaso-occlusive crisis; sGC soluble guanylcyclase;
GSH: glutathione; NAC: N-acetyl-cysteine; GA: gum arabic.
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Crizanlizumab is a humanized P-Selectin antibody, which has
been tested in a multinational double-blind placebo-controlled
trial (SUSTAIN, #NCT0185361) [17,58]. SCD subjects (SS, SC, Sβ+,
and Sβ0 genotype) were treated with Crizanlizumab either 2.5 or
5 mg/kg every 4 weeks. Crizanlizumab at the dosage of 5 mg/kg
every 4 weeks reduced the number of pain crisis and increased
the time between VOCs in SCD independently from possible
preceding HU treatment [17,58,59].
An additional strategy targeting P-Selectins is represented by
the use of low-molecular weight heparins, such as Tinzaparin,
which has been shown to block the P-Selectin system and to
reduce the duration and the severity of VOCs in few cases of SCD
patients [14,22]. Sevuparin is a derivative of low-molecularweight
heparin, lacking anticoagulant activity and it has been evaluated
in SCD [56,61]. Sevuparin acts on multiple targets: (i) P- and
L-selectins; (ii) thrombospondin-Fibronectin-Von Willebrand fac-
tor; and (iii) sickle-leukocyte-endothelial cells interaction.
Although Sevuparin is an attractive molecule with multimodal
profile in SCD, the phase II multicenter international trial failed to
show benefit in SCD patients during acute VOCs (https://www.
modustx.com/modus-therapeutics-announces-the-results-of-its-
global-randomized-placebo-controlled-phase-2-clinical-trial/).
Another possible strategy to interfere with sickle cell-related
pro-adhesion is to modulate/block the activation of comple-
ment, which has been linked to chronic inflammation [62,63].
Previous studies revealed (i) an activation of the alternative
complement pathway (AP) of complement activation in SCD
patients; (ii) a reduction in the activating proteases factor B and
D, modulating complement activation; (iii) a decrease in the
plasma levels of FH, the major soluble regulator of AP activa-
tion; and (iv) increased deposition of the complement opsonin
C3b on RBC exposing phosphatidylserine (PS) [64–71].
Preliminary data from a mouse model for SCD suggest
a possible role for complement activation in the generation of
VOCs, as an additional disease mechanism contributing to the
severity of acute clinical manifestations related to SCD
[63,72,73]. We recently reported that FH acts by preventing
the adhesion of sickle red cells to P-selectin and/or the receptor
Mac-1 receptor (CD11b/CD18), supporting the activation of the
alternative pathway of complement as an additional mechan-
ism in the pathogenesis of acute sickle cell-related VOCs. Our
findings suggest that targeting complement opsonization and/
or opsonin-mediated cell adhesion could provide an alternative
strategy. Whereas the use of exogenous full-length FH as
a therapeutic tool is associated with some challenges for
being used as a therapeutic, several smaller variants of the
regulator have shown promise in preclinical trials for comple-
ment-mediated diseases such as PNH. Owing to the importance
of FH domains 19–20 for interfering with RBC adhesion, mini-FH
constructs containing this domain pair may be considered,
since they may affect both AP activity and the adhesive func-
tion of existing opsonins [74,75]. Alternatively, blocking opsoni-
zation itself at the level of C3 activation is also expected to
impair complement-mediated adhesion. Thus, our data provide
a rationale for further investigation of the potential contribution
of factor-H and other modulators of the alternative comple-
ment pathway with potential implications to the treatment of
sickle cell disease [62].
Figure 2. Schematic diagram of the mechanisms of action of pathophysiology-based new therapeutic options for treatment of sickle cell disease and sickle cell
vasculopathy as well as for hydroxyurea (HU, in yellow). In brown, we show the agents in late-stage clinical development. In blue, we present molecules in early
stage clinical trial or in pre-clinical development. FH: factor H; HbF: fetal hemoglobin; NAC: N-acetyl-cysteine; GA: gum arabic; PUFA: polyunsaturated fatty acid; PDE-
9: phosphodiesterase-9; PS: phosphatidyl-serine; MP: microparticles; ET-1: endothelin-1, IL-1b: interleukin-1, TNF-α: tumor necrosis factor-alpha; NO: nitric oxide. (*)
When this review was under editing, preliminary data of the phase 3 trial with Rivipansel (RESET) were released from Pfizer. Rivipansel treatment did not modify the
time of patient discharge for acute VOCs (primary endpoint) and changes in opioid treatment.
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An attempt to target inflammatory vasculopathy and to
modulate inflammatory response has been made based on
the evidences in other diseases such as in cardiovascular dis-
ease looking to dietary manipulation with omega-3 fatty acids
(ω-3 PUFAs). Supplementation with omega-3 fatty acids has
been reported to (i) beneficially affect red cell membrane lipid
composition; (ii) modulate soluble and cellular inflammatory
response and coagulation cascade; and (iii) to favor NO pro-
duction [76–79]. In SCD, the fatty acid profile of sickle erythro-
cytes is altered compared to healthy controls, with a relative
increase in the ratio of ω-6 to ω-3 PUFAs, in agreement with
sustained chronic inflammation [80,81]. In humanized mouse
model for SCD, PUFA supplementation protects against acute
sickle cell-related lung and liver damages during hypoxia/
reoxygenation-induced VOCs [16]. A phase II multicenter ran-
domized double-blind placebo-controlled study in SCD
patients reported that SCA411, a novel docosahexaenoic acid
(DHA) formulation with increased bioavailability, reduced pro-
inflammatory markers, and ameliorates home management of
pain with a positive trend in decreasing pain episode in SCD
subjects without reaching statistical significant differences
when compared to placebo group (SCOT, #NCT02973360)
[82–85]. Noteworthy, SCA411 (20–36 mg/Kg/day for 8 weeks)
administrated in combination with HU in children with SCD
showed a safe profile with a good tolerability. Further studies
are required to definitively confirm the positive effect of
SCA411 supplementation in SCD patient refractory/or still
symptomatic under HU treatment [83].
Novel therapeutic options focusing on physiological process
promoting resolution of inflammation are of interest for treat-
ing acute events and for prevention of SCD-related vasculopa-
thy. The resolution process is actively controlled by the
temporal and local production of specialized proresolving lipid
mediators (SPM). These include lipoxins (LX), resolvins (Rv),
protectins, and maresins from polyunsaturated fatty acids [19].
In humanized mouse model for SCD, Matte et al. demonstrate
novel protective actions of 17R-RvD1 (7S,8R,17R-trihydroxy-
4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid), a member of
endogenous lipid mediators, which play a key role in the
resolution of inflammation-related pathologies [19]. The admin-
istration of 17R-RvD1 reduces ex vivo human SCD blood leuko-
cyte recruitment by microvascular endothelial cells and in vivo
neutrophil adhesion and transmigration.
The mechanism of action of 17R-RvD1 is based on
a blunting of the activation of NF-κB and reduction of pro-
inflammatory cytokines with the modulation of vascular
endothelial activation. Based on data in humanized mouse
model for SCD, Matte et al. suggest that SCD subjects may
be more vulnerable to inflammatory vasculopathy due to
altered pro-resolving processes (Figure 1) [19].
The combination of HU with L-arginine has been evaluated in
a phase II clinical trial and in a couple of national double-blind
randomized trials [86–90]. Low-arginine bioavailability charac-
terizes SCD. NO is generated from L-arginine and L-citrulline by
endothelial cells via constitutive (eNOS) and inflammatory indu-
cible nitric oxide synthases (iNOS). In SCD, chronic hemolysis
leading to increase in the plasma levels of hemoglobin that is
an efficient NO buffer, contributes to reducing NO levels in SCD.
Thus, the supplementation with either L-arginine or L-citrulline
has been evaluated as possible additional strategy against SCD-
related inflammatory vasculopathy [8,91–96]. Nitric oxide (NO) is
a potent vasodilator and inhibitor of vascular remodeling and
affects the multi-step cascade of events involved in leukocyte,
platelet, and endothelial activation. In SCD, supplementation
with L-arginine in combination with HU has been shown to
beneficially impact sickle cell-related pain, leg ulcers, and pul-
monary hypertension [86–90]. Thus, L-arginine might be consid-
ered as an interesting adjuvant in combination with HU in the
clinical management of patients with SCD. Recently, Majumdar
et al. have reported a single-center open-label trial to evaluate
the safety and tolerability of L-citrulline infusion (50 mg/mL) in
patients with SCD under steady state conditions [97]. L-Citrulline
was well tolerated without major events except for drowsiness
that was recorded in 6 out of 8 L-citrulline treated SCD patients.
An additional strategy to potentiate cellular effects of NO is
represented by agents targeting soluble guanylcyclase (sGC),
the only known NO receptor. These molecules might be
divided into stimulators or activators of sGC, ending in
increased intracellular cGMP content that modulates vascular
tone and inflammatory response [98,99]. Among the sGC sti-
mulators, Riocinguat (BAY63-2521) and Olinciguat (IW-1701)
have been studied in patients with SCD. Riocinguat is an oral
sGC activator with very short half-life, showing some beneficial
effects in a case series of SCD patients with chronic throm-
boembolic pulmonary embolism [100]. Olinciguat is a once-
a day oral sGC stimulators, which received an FDA orphan
drug designation for SCD. A phase II double-blind placebo-
controlled trial (NCT#03285178) is now enrolling SCD patients
to evaluate the safety and tolerability profile of this drug.
Combination therapy of sGC with HU might be considered
to potentiate the beneficial effects of HU on NO metabolism.
Up to now, sGC activators have been only tested in animal
models for SCD [98].
2.2. Antioxidant agents and sickle cell disease
SCD is also characterized by a highly pro-oxidant environment
due to the elevated production of reactive oxygen species
(ROS) generated by increased levels of pathological free
heme and iron and a reduction in antioxidant systems such
as GSH (Figure 2) [6,8,14,101,102]. N-Acetyl-cysteine (NAC), an
exogenous thiol donor, has been studied both in vitro and
in vivo in SCD patients. NAC supplementation (1200–2400 mg/
day) was shown to reduce the formation of dense red cells
and the rate of hemolysis and to increase GSH levels in SCD
subjects. However, Sins et al. recently reported a randomized,
placebo-, double-blind trial (#NCT01849016) on NAC in SCD.
Although the study shows a failure of NAC in affecting acute
clinical manifestations of SCD, a low adherence of SCD
patients to NAC treatment was observed and this might be
responsible for the reduced biological effect of NAC in SCD.
A clinical trial with high dose of NAC during acute VOCs
related to SCD is ongoing (#NCT 01800526) [103–105].
L-Glutamine is a likely antioxidant agent in SCD. Glutamine is
involved in GSH metabolism since it preserves NADPH levels
required for GSH recycling, and it is the precursor for nicotina-
mide adenine dinucleotide (NAD) and arginine [106–108].
Recently, a multicenter, randomize, placebo-controlled double-
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blind phase III clinical trial with L-glutamine (0.3 g/kg twice a day)
involving 230 SS and Sbeta0 patients with ≥2 pain crisis showed
that L-glutamine supplementation reduced the mean number
and length of hospitalization, associated with increased median
time to the first crisis [106]. Both studies have several limitations
such as (i) the high rate of patient drop-out; (ii) the presence of
fatal events due to multiorgan failure in L-glutamine arm; (iii) the
lack of effects on hematologic parameters and hemolytic indices;
and (iv) the absence of clear data on L-glutamine mechanism of
action [106,109].
Another antioxidant molecule recently investigated in
phase II clinical trial in SCD is gum arabic (GA) exudates
mechanically extracted from Acacia senegal [110]; 47 SCD
patients (aged 5–42 years) were treated with GA at the dosage
of 30 g/day for 3 months [110]. The authors observed an
improvement of serum total antioxidant capacity and malon-
dialdehyde (MDA) levels in SCD patients treated with GA.
Although the data are interesting particularly in respect to
the site where the study was carried out, limited information
are available on the effect of GA on hematologic parameters
and the quality of GA as chemical profile and purity.
3. Conclusion
We are now in a new era for SCD which is characterized by the
emergence of novel treatments and the enhancement of
patient survival and where a holistic approach should offer
an improvement of patient quality of life. This might redirect
clinicians and scientists to consider the new field of combina-
torial therapy with or without HU [111]. Moreover, long-term
studies should be designed to evaluate the real impact of new
and emerging agents on natural history of SCD. Soon, we
hope that more clinical studies will be reported by African
researchers who can contribute to building a global collabora-
tion for the enrichment of SCD management and treatment.
4. Expert opinion
Studies have shown that hemoglobinopathies such as sickle
cell disease are in the top 10 causes of anemia and are
associated with an increase in years lived with disability
[2,112]. Thus, hemoglobinopathies heavily impact patient sur-
vival, quality of life, and global health costs. The available
therapeutic tools for clinical management of SCD are HU,
different transfusion regimes, and hematopoietic stem cell
transplantation with the latter as curative approach to SCD.
Although progress has been made on SCD clinical manage-
ment, mortality, and morbidity of patients with SCD is still
high relative to healthy subjects [113,114]. The key question
is what do we need for patients with SCD? We believe that we
should seek intensive treatment to impact SCD natural history
and reduce the severity/recurrence of acute VOCs. We know
from HU that multimodal therapy could be the key to prevent
SCD progression. Thus, therapeutic targets such as neutrophils
and inflammatory vasculopathy should be considered as sig-
nificant contributors to the biocomplexity of sickle cell-related
clinical manifestations. This is very important for patients eli-
gible for curative approaches such as bone marrow stem cell
treatment (BMSCT) or gene therapy [115]. Recently, lentiviral
(LV) gene therapy based on the addition of an anti-sickling
globin gene has been reported to be safe and positively
impact the hematologic phenotype in a child with SCD [116].
Clinical trials using LV-gene therapy are ongoing in SCD
[115,117–119]. Another possible gene therapy strategy targets
the up-regulation of endogenous HbF expression by suppres-
sion/modulation of Bcl11A in erythroid cells progenitors
[120,121]. Preliminary data in an SCD patient indicate
a significant increase in HbF expression which successfully
reached 23% of total Hb [120]. Finally, the development of
CRISPR/Cas9 genome editing (GE) strategy represents another
new potential therapeutic tool for the genetic correction of
SCD [122]. This might be less expensive than LV-based gene
therapy [123–125]. Gene therapy appears to be very attractive
as a cure; however, this may be met with caution by research-
ers and clinicians because of limiting factors such as mutagen-
esis, conditioning regimen, or high costs.
Pharmacogenomic studies are potentially beneficial for the
identification of key genomic variants for inflammatory vascu-
lopathy, inflammasome or pain in SCD. However, these studies
are limited and have only recently involved sub-Saharan coun-
tries where most SCD patients live [126–130]. Hence, new
pharmacogenomic studies should be designed to involve mul-
tiple sites in different settings to progress the development of
algorithm(s) that might assist in the development of persona-
lized medicine [126]. At least a decade is required to evaluate
the real impact of the new therapeutic options on SCD. For
now, our efforts should be devoted to offering the best clinical
management and accessibility to standard goal treatment,
especially in less developed countries.
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